Get the Stockscreener App
1.21
6.92%
-0.09
After Hours:
1.22
0.01
+0.83%
Inovio Pharmaceuticals Inc stock is traded at $1.21, with a volume of 4.11M.
It is down -6.92% in the last 24 hours and up +11.01% over the past month.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
See More
Previous Close:
$1.30
Open:
$1.3
24h Volume:
4.11M
Relative Volume:
1.29
Market Cap:
$125.11M
Revenue:
$65,300
Net Income/Loss:
$-84.93M
P/E Ratio:
-0.7084
EPS:
-1.708
Net Cash Flow:
$-83.57M
1W Performance:
+34.43%
1M Performance:
+11.01%
6M Performance:
-30.06%
1Y Performance:
-34.59%
1-Day Range:
$1.20
$1.30
1-Week Range:
$0.8978
$1.3191
52-Week Range:
$0.5632
$2.9789
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Name
Inovio Pharmaceuticals Inc
Sector
Industry
Phone
(858) 410-3134
Address
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.21 | 134.42M | 65,300 | -84.93M | -83.57M | -1.708 |
VRTX
Vertex Pharmaceuticals Inc
|
540.26 | 139.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
826.64 | 86.57B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,038.12 | 64.62B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
133.32 | 69.62B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.74 | 46.01B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Piper Sandler | Overweight |
| May-14-24 | Initiated | Stephens | Overweight |
| Jan-25-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-09-22 | Downgrade | Maxim Group | Buy → Hold |
| Nov-01-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-19-22 | Resumed | RBC Capital Mkts | Sector Perform |
| May-11-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-29-21 | Resumed | Jefferies | Hold |
| Sep-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-24-21 | Initiated | Jefferies | Hold |
| Mar-23-21 | Initiated | BofA Securities | Neutral |
| Feb-12-21 | Initiated | Oppenheimer | Outperform |
| Nov-17-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Nov-10-20 | Upgrade | ROTH Capital | Sell → Neutral |
| Sep-28-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-28-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-01-20 | Downgrade | Maxim Group | Buy → Hold |
| Jul-01-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Jun-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-26-20 | Downgrade | Stifel | Buy → Hold |
| May-21-20 | Initiated | The Benchmark Company | Buy |
| Apr-30-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Mar-13-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-13-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-19-19 | Initiated | ROTH Capital | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
| Oct-18-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Initiated | Citigroup | Buy |
| Jun-08-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-24-17 | Reiterated | Maxim Group | Buy |
| Mar-16-17 | Upgrade | Maxim Group | Hold → Buy |
| Mar-16-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
View All
Inovio Pharmaceuticals Inc Stock (INO) Latest News
Inovio Pharmaceuticals Company Profile & Introduction - Moomoo
INO, MRNA, NVAX, EBS Jump Overnight: Trump Promises Full Hantavirus Report As Deadly Outbreak Sparks Vaccine Rally - Stocktwits
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio (INO) Earnings Check: The Available Earnings Metric Delivers a Beat at the Close; Post-Report Move: The Stock Ends Up 4.35% in the Latest ReadingFinancial Data - Vinanet
Q3 EPS Estimate for Inovio Pharmaceuticals Raised by Analyst - MarketBeat
INO Jumps As Inovio Wins Upgrade Ahead Of FDA Decision - timothysykes.com
Inovio Stock Jumps As Jefferies Upgrade Bets On FDA Decision - StocksToTrade
Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to "Hold" at Wall Street Zen - MarketBeat
INOVIO Sets Aug. 12 Earnings Update With Business Review - MyChesCo
Inovio Pharmaceuticals Highlights FDA Inspection Completion and INO-3107 Regulatory Progress in Q2 2026 Earnings CallDividend Earnings Report - Vinanet
HC Wainwright Issues Negative Estimate for INO Earnings - MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to Strong-Buy at Zacks Research - MarketBeat
INO Upgraded by Jefferies -- Price Target Raised to $3.00 - GuruFocus
Piper Sandler Maintains Inovio Pharmaceuticals(INO.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Jefferies Maintains Inovio Pharmaceuticals(INO.US) With Buy Rating, Raises Target Price to $3 - Moomoo
H.C. Wainwright reiterates Neutral on Inovio stock, $2.50 target - Investing.com
H.C. Wainwright reiterates Neutral on Inovio stock, $2.50 target By Investing.com - Investing.com Canada
Jefferies upgrades Inovio stock rating on FDA review progress - Investing.com
Inovio Q2 2026 slides: INO-3107 on track for Oct FDA decision - Investing.com Nigeria
Jefferies upgrades Inovio stock rating on FDA review progress By Investing.com - Investing.com Canada
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO): What Does the Latest Update Mean for Regulatory Progress? - Kalkine Media
INOVIO PHARMACEUTICALS INC : JEFFERIES RAISES TO BUY FROM HOLD; RAISES TARGET PRICE TO $3 FROM $1.8 - Bitget
Inovio Pharmaceuticals Inc (INO) (Q2 2026) Earnings Call Highlights: INO-3107 on Track for ... - Yahoo Finance
Inovio Pharmaceuticals Inc (INO) (Q2 2026) Earnings Call Highlig - GuruFocus
Inovio Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Inovio Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:INO) 2026-08-12 - Seeking Alpha
Inovio (INO) Q2 2026 Earnings Call Transcript - theglobeandmail.com
Inovio Pharmaceuticals, Inc. (INO) stock price, news, quote and history - Yahoo Finance UK
Inovio Q2 EPS $(0.07) beats $(0.22) estimate; loss narrows 74% - scanx.trade
Inovio Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPS - MarketBeat
Earnings call transcript: Inovio narrows Q2 2026 loss as INO-3107 nears FDA date - Investing.com
Inovio Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Q2 2026 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Inovio: Q2 Earnings Snapshot - marketscreener.com
BRIEF-Inovio Pharmaceuticals Q2 Operating Expenses USD 18.6 Million - TradingView
INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Yahoo Finance
Adage Capital (INO) discloses 3.43M Inovio shares via warrants in 13G/A - Stock Titan
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - AOL.com
Inovio Pharmaceuticals (NASDAQ:INO): What Could Today’s pipeline focus and funding discipline Update Reveal? - Kalkine Media
Inovio Pharmaceuticals Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
Inovio Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Q1 2026 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
RA Capital reports 10.67M-share Inovio (NASDAQ: INO) stake capped at 9.99% - Stock Titan
INO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce - The National Law Review
Inovio Pharmaceuticals (INO.US) will release its earnings report after market close on August 12. - Moomoo
FMR LLC (INO) discloses 8.45M Inovio shares, including major fund holder - Stock Titan
Inovio Pharmaceuticals (INO) Projected to Release Earnings on Wednesday - MarketBeat
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
INOVIO to Report Second Quarter Financial Results on August 12, 2026 - TradingView
Inovio Pharmaceuticals Inc Stock (INO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):